Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

UKPTO grants arGEN-X patent covering SIMPLE Antibody platform

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies using its proprietary SIMPLE Antibody(TM) platform, announces that it has been granted the first patent covering the platform. The patent GB2461546B, has been granted by the UK Patent and Trademark Office (UKPTO).

9 Jul 2010

ITelagen to provide EHR, outsourced billing and IT support for Canterbury Medical Associates

ITelagen, a leading provider of Healthcare IT solutions, was selected by Christ Hospital to provide electronic health records (EHR) as part of an entire back-office solution that includes outsourced billing and unlimited IT support for their affiliate Canterbury Medical Associates.

9 Jul 2010

Bayer HealthCare to present BAY86-6150 rFVIIa Phase I clinical data at XXIX WFH International Congress

Phase I clinical data for BAY86-6150, a novel recombinant factor VIIa protein (rFVIIa) being developed by Bayer HealthCare, will be presented at the XXIX International Congress of the World Federation of Hemophilia (WFH) to be held in Buenos Aires, Argentina from Saturday, July 10-Wednesday, July 14.

9 Jul 2010

Roche Molecular Systems receives FDA clearance for new LightCycler MRSA Advanced Test

Roche Molecular Systems, Inc. announced today that the U.S. Food & Drug Administration (FDA) cleared its new LightCycler® MRSA Advanced Test for the detection of methicillin-resistant Staphylococcus aureus (MRSA) for clinical use in the United States.

9 Jul 2010

Infinity obtains global rights to Intellikine's portfolio of inhibitors of delta and gamma isoforms of PI3K

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, and Intellikine, Inc., a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, today announced an agreement under which Infinity obtained global development and commercialization rights to Intellikine's portfolio of inhibitors of the delta and gamma isoforms of phosphoinositide-3-kinase.

8 Jul 2010

Calithera Biosciences completes Series A financing totaling $40M

Calithera Biosciences, a company developing novel oncology therapeutics, today announced the completion of a Series A financing totaling $40 million. Morgenthaler Ventures led the financing with U.S. Venture Partners, Advanced Technology Ventures, Delphi Ventures and Mission Bay Capital also participating in the round. The capital will be used to support the company's pioneering efforts to develop activators of caspases, the proteases that promote apoptotic cell death, for the treatment of cancer and other proliferative diseases.

8 Jul 2010

Advanced Life Sciences announces positive results from preclinical studies of Restanza IV

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced positive results from preclinical toxicology and pharmacokinetic studies of an intravenous (IV) formulation of its novel antibiotic, Restanza™ that support its use in a hospital setting.

8 Jul 2010

Kiadis Pharma receives FDA approval for IND to start pivotal clinical study for ATIR

Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start the pivotal clinical study for its product ATIR™ in the United States. Kiadis Pharma is currently enrolling patients in a multinational, pivotal clinical study at hospitals in Europe and Canada. With the approval of the IND, US hospitals will also participate in this study.

8 Jul 2010

SIR and 41 international societies issue first global statement defining interventional radiology

The Society of Interventional Radiology, with the support of 41 international societies representing 10,000 interventional radiology doctors, has issued the first global statement defining interventional radiology-one designed to benefit medical treatment for individuals. The statement addresses the evolution, impact and future direction of this minimally invasive specialty, emphasizing the worldwide availability of this specialized medical care.

8 Jul 2010

ESMO releases revised set of clinical guidelines for cancer patient care

The European Society for Medical Oncology just released an enhanced and revised set of clinical recommendations designed to help oncologists deliver the best quality care to their patients.

8 Jul 2010

Scientists shrink distant sarcomas with genetically reprogrammed herpes virus and anti-vascular drug

Scientists have used a genetically reprogrammed herpes virus and an anti-vascular drug to shrink spreading distant sarcomas designed to model metastatic disease in mice – still an elusive goal when treating humans with cancer, according to a study in the July 8 Gene Therapy.

8 Jul 2010

Selvita, Orion collaborate to develop and commercialize SEL103 Alzheimer’s disease program

Selvita sp. z o.o., from Krakow, Poland and Orion Corporation from Espoo, Finland (ORNBV) today announced that they have entered into a global collaboration to jointly develop and commercialize SEL103, Selvita's proprietary program for the treatment of Alzheimer's disease and other cognitive disorders. Selvita will be responsible for early research on the program and Orion will take over the pre-clinical and clinical development as well as further commercialization.

8 Jul 2010

Silence strengthens RNAi IP portfolio with issuance of key patent in structural modification technology

Silence Therapeutics plc announces the issuance of United States patent 7,750,144, titled Methods and Compositions for Enhancing Efficacy and Specificity of RNA Silencing, by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of producing double stranded (RNAi) agents having decreased off-target silencing activity through certain structural modifications. The ability to minimize the off-target effects of RNAi therapeutics is critical for controlling unwanted cellular activity and/or potential safety concerns.

8 Jul 2010

Aethlon Medical files provisional patent on behalf of ESI for exosome detection assay

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has filed a provisional patent on behalf of its wholly owned subsidiary Exosome Sciences, Inc. (ESI), relating to the development of an assay that will allow researchers to detect exosomes in blood and other fluids.

8 Jul 2010

Omni Health Media announces launch of CancerConnect.com

Omni Health Media, one of the world's leading specialty publishers of health-related information, websites, applications, and educational programs for individuals with cancer and their caregivers announces the successful launch of CancerConnect.com during the Allen Media Conference in Sun Valley, ID. Cancer Connect is a new social network that will allow people with cancer and those who care for them to share information, inspiration, hope, and support.

8 Jul 2010

Clinical performance data of Cervista HPV HR presented at International Papillomavirus Conference

Hologic, Inc., a leading women's healthcare company, today announced that final data analysis from the first large-scale independent evaluation of clinical performance of Cervista HPV HR compared to Hybrid Capture 2, were presented in Montreal, Canada, at the 26th International Papillomavirus Conference. Cervista HPV HR is a diagnostic test for the detection of 14 high-risk human papillomavirus types.

8 Jul 2010

Scientists use genetically reprogrammed herpes virus to shrink distant sarcomas

Scientists have used a genetically reprogrammed herpes virus and an anti-vascular drug to shrink spreading distant sarcomas designed to model metastatic disease in mice - still an elusive goal when treating humans with cancer, according to a study in the July 8 Gene Therapy.

8 Jul 2010

Olaparib shows promising results against inherited forms of breast and ovarian cancer

Olaparib, a new type of experimental drug called a PARP inhibitor, has shown promising results against inherited forms of breast and ovarian cancer in two small clinical trials led by scientists at the Breakthrough Breast Cancer Research Unit at King's College London.

8 Jul 2010

Neoprobe initiates third multi-center Phase 3 clinical study of Lymphoseek

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that a third multi-center Phase 3 clinical study of Lymphoseek (NEO3-09) has received investigational review board approval and begun enrollment of subjects diagnosed with breast cancer or melanoma.

7 Jul 2010

Insights into complex interrelationships between heart and kidneys

Research is yielding new understanding of the interactions between the heart and the kidneys—particularly the cardiorenal syndrome, in which failure of either organ can lead to failure of the other. Recent insights into the complex interrelationships between the heart and kidneys are presented in a special symposium section of the July issue of The American Journal of Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation.

7 Jul 2010

Oncology News and Research

Further Reading

UKPTO grants arGEN-X patent covering SIMPLE Antibody platform

ITelagen to provide EHR, outsourced billing and IT support for Canterbury Medical Associates

Bayer HealthCare to present BAY86-6150 rFVIIa Phase I clinical data at XXIX WFH International Congress

Roche Molecular Systems receives FDA clearance for new LightCycler MRSA Advanced Test

Infinity obtains global rights to Intellikine's portfolio of inhibitors of delta and gamma isoforms of PI3K

Calithera Biosciences completes Series A financing totaling $40M

Advanced Life Sciences announces positive results from preclinical studies of Restanza IV

Kiadis Pharma receives FDA approval for IND to start pivotal clinical study for ATIR

SIR and 41 international societies issue first global statement defining interventional radiology

ESMO releases revised set of clinical guidelines for cancer patient care

Scientists shrink distant sarcomas with genetically reprogrammed herpes virus and anti-vascular drug

Selvita, Orion collaborate to develop and commercialize SEL103 Alzheimer’s disease program

Silence strengthens RNAi IP portfolio with issuance of key patent in structural modification technology

Aethlon Medical files provisional patent on behalf of ESI for exosome detection assay

Omni Health Media announces launch of CancerConnect.com

Clinical performance data of Cervista HPV HR presented at International Papillomavirus Conference

Scientists use genetically reprogrammed herpes virus to shrink distant sarcomas

Olaparib shows promising results against inherited forms of breast and ovarian cancer

Neoprobe initiates third multi-center Phase 3 clinical study of Lymphoseek

Insights into complex interrelationships between heart and kidneys

Cancer Research eBook

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News